Sujata Tyagi Dayal sold $116k of EBS
director at Emergent BioSolutions Inc.. 13,761 shares at an average of $8.40, traded May 1, 2026, filed May 4, 2026.
Score components
- +15RoleDirector
- +10Trade size$116k at market
- +5Share of holdings soldSold 12% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.1%, 3m -13.2%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001536908-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 30, 2026 | AGrant or award Common Stock10b5-1 | +25,344 | $0.00 | $0 | 114,324 | May 4, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -12,781 | $8.36 | $107k | 101,543 | May 4, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -980 | $8.94 | $8,761 | 100,563 | May 4, 2026 |
| Apr 30, 2026 | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +11,296 | $0.00 | $0 | 11,296 | May 4, 2026 |
Related signals
Other insiders at Emergent BioSolutions Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 14, 2026 | Emergent BioSolutions Inc. | Donald W DeGolyer director | $126k 17,800 shares | -14% | |
| 3Weak | Emergent BioSolutions Inc. | Paul Anthony Williams SVP, Products Business | $20k 3,000 shares | -2% | |
| 0Weak | Emergent BioSolutions Inc. | Paul Anthony Williams SVP, Products Business | $25k 3,000 shares | -2% | |
| 26Weak | Emergent BioSolutions Inc. | Donald W DeGolyer director | $130k 15,481 shares | -11% | |
| 26Weak | Emergent BioSolutions Inc. | Keith Katkin director | $128k 15,481 shares | -14% | |
| 26Weak | Emergent BioSolutions Inc. | Kathryn C Zoon director | $144k 17,202 shares | -18% | |
| 1Weak | Emergent BioSolutions Inc. | Paul Anthony Williams SVP, Products Business | $34k 4,000 shares | -6% | |
| 18Weak | EBSsell Emergent BioSolutions Inc. | Ronald Richard director | $263k 21,984 shares | -21% | |
| 20Weak | Emergent BioSolutions Inc. | Donald W DeGolyer director | $188k 17,801 shares | -13% | |
| 12Weak | Emergent BioSolutions Inc. | Sujata Tyagi Dayal director | $86k 8,552 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.